Table II.
Clinicopathological features of study cohort, associations with p27 IHC and subsets of ERG-negative and -positive cancers.
| p27 IHC result (all cancers/ERG-negative/ERG-positive) | |||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| Parameter | n all | n evaluable | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | P-value |
| All cancers | 4699 | 3701 (1876/1709) | 18.6 (27.8/7.5) | 33.5 (36.9/30.3) | 28.4 (22.9/34.7) | 19.5 (12.4/27.5) | |
| Tumor stage | |||||||
| pT2 | 3019 | 2338 (1260/994) | 20.1 (29.5/7.0) | 32.9 (36.0/29.5) | 27.9 (22.6/34.7) | 19.2 (11.9/28.8) | 0.0185 (0.0758/0.2009) |
| pT3a | 946 | 778 (342/420) | 15.8 (23.1/8.1) | 33.3 (39.8/28.8) | 29.1 (22.0/35.2) | 21.9 (15.2/27.9) | |
| ≥pT3b | 527 | 461 (216/231) | 15.0 (22.2/8.7) | 37.5 (38.0/37.2) | 29.5 (26.4/32.0) | 18.0 (13.4/22.1) | |
| Gleason grade | |||||||
| ≤3+3 | 1765 | 1279 (675/552) | 25.5 (37.9/9.2) | 32.1 (35.1/29.7) | 25.9 (20.3/32.6) | 16.5 (6.7/28.4) | <0.0001 (<0.0001/0.5422) |
| 3+4 | 2074 | 1715 (823/894) | 15.0 (23.0/6.6) | 34.5 (38.9/30.5) | 29.3 (23.9/34.9) | 21.2 (14.2/28.0) | |
| 4+3 | 528 | 435 (229/193) | 14.9 (19.7/7.8) | 34.0 (37.6/30.1) | 30.1 (23.1/38.3) | 20.9 (19.7/23.8) | |
| ≥4+4 | 166 | 145 (88/51) | 8.3 (10.2/3.9) | 33.1 (30.7/37.3) | 34.5 (33.0/35.3) | 24.1 (26.1/23.5) | |
| Lymph node metastasis | |||||||
| N0 | 2359 | 1837 (916/877) | 16.2 (23.9/7.4) | 34.0 (37.7/30.7) | 29.5 (24.5/34.9) | 20.3 (14.0/27.0) | 0.9015 (0.1647/0.6316) |
| N+ | 174 | 150 (73/73) | 14.0 (17.8/8.2) | 34.0 (32.9/35.6) | 30.7 (26.0/35.6) | 21.3 (23.3/20.6) | |
| Preoperative PSA level (ng/ml) | |||||||
| <4 | 672 | 493 (217/247) | 17.0 (26.7/7.7) | 30.0 (33.2/27.1) | 31.9 (26.3/36.4) | 21.1 (13.8/28.8) | 0.002 (0.1787/0.0023) |
| 4–10 | 2585 | 2060 (1039/964) | 17.9 (27.6/6.2) | 33.7 (38.0/30.0) | 27.3 (20.1/34.1) | 21.0 (13.8/29.8) | |
| 10–20 | 909 | 734 (413/303) | 21.4 (30.0/9.2) | 33.8 (35.6/31.0) | 30.0 (24.7/38.3) | 14.9 (9.7/21.5) | |
| >20 | 311 | 249 (134/107) | 18.1 (20.9/13.1) | 39.8 (39.6/41.1) | 24.1 (26.1/21.5) | 18.1 (13.4/24.3) | |
| Surgical margin | |||||||
| Negative | 3665 | 2866 (1473/1299) | 18.5 (27.5/7.3) | 33.7 (37.1/30.3) | 27.9 (22.9/34.0) | 19.8 (12.6/28.5) | 0.6104 (0.9984/0.3255) |
| Positive | 844 | 687 (328/340) | 18.5 (27.5/8.5) | 32.9 (36.9/30.6) | 30.3 (22.8/37.1) | 18.3 (12.8/23.9) | |
IHC, immunohistochemistry; PSA, prostate-specific antigen.